Clinical trials for quality-of-life assessment

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44381 clinical trials with a EudraCT protocol, of which 7393 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (3,321)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

3,321 result(s) found for: quality-of-life assessment. Displaying page 16 of 167.

EudraCT Number: 2011-002825-22	Sponsor Protocol Number: PROPUDO	Start Date*: 2011-12-29
Sponsor Name:Hospital General Universitario de Alicante
Full Title: Pilot, placebo-controlled, double-blind, randomized, parallel propofol effective in preventing refractory chronic migraine
Medical condition: Refractory chronic migraine
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2018-002471-18

Sponsor Protocol Number:

Start Date*: 2019-01-18

Sponsor Name:Imperial College London

Full Title: The clinical effectiveness and cost effectiveness of clozapine for inpatients with borderline personality disorder: randomised controlled trial

Medical condition: Borderline Personality Disorder

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10037175 - Psychiatric disorders	10006034	Borderline personality disorder	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA)

Trial results: View results

EudraCT Number: 2016-003828-23

Sponsor Protocol Number: ML39310

Start Date*: 2017-04-11

Sponsor Name:Charité - Universitätsmedizin Berlin; Dpt. of Dermatology and Allergy

Full Title: A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS)

Medical condition: Schnitzler’s syndrome (SchS)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.1	10040785 - Skin and subcutaneous tissue disorders	10062908	Schnitzler's syndrome	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2010-021166-30	Sponsor Protocol Number: 2010-SS-Canakinumab	Start Date*: 2010-11-25
Sponsor Name:Radboud University Nijmegen Medical Centre
Full Title: Efficacy and safety of canakinumab in Schnitzler syndrome
Medical condition: Schnitzler syndrome is an acquired autoinflammatory syndrome characterized by urticaria and monoclonal gammopathy, accompanied by intermittent fever, arthralgia or arthritis, bone pain and lymphade...
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NL (Completed)
Trial results: View results

EudraCT Number: 2012-003426-24	Sponsor Protocol Number: CTU079G	Start Date*: 2013-02-13
Sponsor Name:Riemser Pharma GmbH
Full Title: A multicentre double blind placebo controlled clinical trial to assess efficacy and safety of Alvalin® (cathine hydrochloride) vs. placebo in 265 obese patients/group with a body mass index (BMI) b...
Medical condition: diet-related obesity diagnosed by BMI of 30 to 45 kg/m²
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: View results

EudraCT Number: 2017-000545-52

Sponsor Protocol Number: GLPG0634-CL-225

Start Date*: 2017-10-06

Sponsor Name:Galapagos Nv

Full Title: A multicenter, open-label, long-term extension safety and efficacy study of filgotinib treatment in subjects with moderately to severely active psoriatic arthritis

Medical condition: Psoriatic arthritis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004859	10037160	Psoriatic arthritis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) CZ (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended)

Trial results: View results

EudraCT Number: 2022-001522-30	Sponsor Protocol Number: RIMOFATSCI-2	Start Date*: 2022-10-03
Sponsor Name:Fundación Hospital Nacional de Parapléjicos
Full Title: Effects of a CB1 receptor reverse antagonist/agonist (Rimonabant) on wandering ability in patients with incomplete spinal cord injuries
Medical condition: Possibility of improving wandering in patients. The effects of Rimonabant on other functional measures will be assessed and it will be confirmed that it is a safe treatment in the study population.
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2013-002106-31	Sponsor Protocol Number: 44512	Start Date*: 2014-04-01
Sponsor Name:Academic Medical Center
Full Title: The DANCE study: Duration of ANtibiotic therapy for CEllulitis
Medical condition: Cellulitis (Cellulitis is a common acute, spreading pyogenic inflammation of the skin (dermis) and subcutaneous tissue, usually complicating a wound, ulcer or dermatosis)
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NL (Prematurely Ended)
Trial results: View results

EudraCT Number: 2010-024202-34

Sponsor Protocol Number: 24122010

Start Date*: 2014-04-24

Sponsor Name:UNIVERSITÄTSMEDIZIN GÖTTINGEN, GEORG-AUGUST-UNIVERSITÄT,Klinik für Kinder- und Jugendpsychiatrie/Psychotherapie

Full Title: Effect of oxytocin on therapy results of a group based social skill training in adolescents with Autism Spectrum Disorder

Medical condition: high-functioning autismus spectrum disorders: autistic disorder (F84.0), Asperger syndrome (F84.5), atypical autism (F84.1)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004873	10021737	Infantile autism	LLT

Population Age: Adolescents, Under 18, Adults

Gender: Male

Trial protocol: DE (Completed)

Trial results: (No results available)

EudraCT Number: 2021-003642-20	Sponsor Protocol Number: CUV156	Start Date*: 2021-09-27
Sponsor Name:CLINUVEL EUROPE LTD
Full Title: A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum (XP)
Medical condition: xeroderma pigmentosum
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-003327-15	Sponsor Protocol Number: TIDAM	Start Date*: 2022-02-21
Sponsor Name:Erasmus MC
Full Title: An open-label, 8-week, proof of concept trial on thymosin-α1 (thymalfasin) in the treatment of primary antibody deficiency (PAD) associated mood disorders (TIDAM18).
Medical condition: Primary immunodeficiency
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NL (Completed)
Trial results: (No results available)

EudraCT Number: 2022-002175-11	Sponsor Protocol Number: 2021-35	Start Date*: 2022-10-25
Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
Full Title: Safety and potential effect of innovative treatment by adjuvant injection of stromal vascular Fraction from autologous adipose tissue of URethral stenosis with endoscopic urethrotomy: randomized co...
Medical condition: URethral stenosis
Disease:
Population Age: Adults, Elderly		Gender: Male
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2019-002629-31	Sponsor Protocol Number: ET19-144	Start Date*: 2021-01-07
Sponsor Name:Centre Léon Bérard
Full Title: REGOMAIN – A randomized, placebo-controlled, double-blinded, multicentre, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients with high grade bone sarcoma...
Medical condition: Patients with high grade bone sarcomas (HGBS) at diagnosis or first relapse and without complete remission after standard treatment
Disease:
Population Age: Adolescents, Under 18		Gender: Male, Female
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2020-002821-28	Sponsor Protocol Number: ET20-128	Start Date*: 2020-12-24
Sponsor Name:Centre Léon Bérard
Full Title: RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma o...
Medical condition: Metastatic or unresectable advanced rare sarcomas
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2022-003009-31

Sponsor Protocol Number: HH007

Start Date*: 2022-12-23

Sponsor Name:Zealand University Hospital, dept. of Haematology

Full Title: Atorvastatin for patients with Philadelphia-negative chronic myeloproliferative neoplasms - Essential thrombocythemia, polycythemia vera and prefibrotic myelofibrosis

Medical condition: Essential thrombocythemia, Polycythemia vera, prefibrotic myelofibrosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10077465	Myeloproliferative neoplasm	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: DK (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2022-000655-36	Sponsor Protocol Number: 80684	Start Date*: 2023-04-06
Sponsor Name:Amsterdam UMC
Full Title: Evaluation of GeranylGeranylAcetone in heart failure with preserved ejection fraction
Medical condition: Heart Failure with preserved ejection fraction.
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NL (Completed)
Trial results: (No results available)

EudraCT Number: 2015-000929-37	Sponsor Protocol Number: EPAG2015	Start Date*: 2018-03-06
Sponsor Name:GOELAMS
Full Title: EPAG 2015 : A phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with acute myeloid leukemia receiving induction chemotherapy
Medical condition: elderly patients > 60 years, with acute myeloid leukemia
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Completed)
Trial results: (No results available)

EudraCT Number: 2021-001555-14	Sponsor Protocol Number: NBK272/1/2021	Start Date*: 2023-01-05
Sponsor Name:Medical University of Gdańsk
Full Title: Assessment of the effect of Wharton's jelly mesenchymal stem cell preparation (WJMSCs) in the treatment of fibrotic interstitial lung diseases
Medical condition: fibrotic interstitial lung disease
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: PL (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2013-002269-21	Sponsor Protocol Number: 01.00240	Start Date*: 2013-12-06
Sponsor Name:Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto
Full Title: Metformin in diastolic dysfunction of metabolic syndrome
Medical condition: Diastolic dysfunction in non-diabetic patients with metabolic syndrome
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: PT (Completed)
Trial results: (No results available)

EudraCT Number: 2021-004131-84

Sponsor Protocol Number: ChronIA001

Start Date*: 2022-02-14

Sponsor Name:Erasmus Medical Center

Full Title: Chronotherapy in Inflammatory Arthritis (ChronIA trial): a randomized controlled trial comparing the effectiveness of morning and evening dosing of tofacitinib extended-release

Medical condition: Rheumatoid arthritis or psoriatic arthritis according to respectively 2010 criteria or CASPAR criteria

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.1	10028395 - Musculoskeletal and connective tissue disorders	10039073	Rheumatoid arthritis	PT
	21.0	10028395 - Musculoskeletal and connective tissue disorders	10037160	Psoriatic arthritis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Trial now transitioned)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Sat Feb 14 14:45:24 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA